Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LLF580 · 1 trial · 1 indication
To assess the safety and tolerability in obese subjects following repeated dosing of LLF580 by subcutaneous (SC) injection over 12 weeks.
| Arm | Type | Description |
|---|---|---|
| LLF580 | EXPERIMENTAL | LLF580 every 28 days \* 3 |
| Placebo | PLACEBO_COMPARATOR | Placebo to LLF580 every 28 days \* 3 |
| Name | Type | Description |
|---|---|---|
| LLF580 | BIOLOGICAL | LLF580 300mg |
| Placebo | DRUG | Placebo to LLF580 |
Inclusion Criteria: * Body mass index (BMI) within the range of 30 to 45 kg/m2, inclusive, with ethnic adjustment (≥27.5 kg/m2 for Asian individuals). * Fasting triglyceride 150 - 500 mg/dL (1.69 - 5.65 mmol/L), inclusive, at screening. * Able to communicate well with the investigator, to understan...
Top 20 of 32 competitors
LLF580 is an investigational monoclonal antibody being developed for the treatment of obesity. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use. The drug is being studied in obese volunteers to evaluate its safety and tolerability.
LLF580 is a monoclonal antibody, a type of biologic drug designed to bind to a specific target in the body. However, the specific molecular target of LLF580 has not been disclosed in available information. The drug is being studied for its potential effects in obesity, but its exact mechanism of action remains undisclosed.
LLF580 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research on this drug for the treatment of obesity.
LLF580 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing to assess its safety and tolerability in humans.
LLF580 has one completed Phase 1 clinical trial registered as NCT03466203, titled "Safety Study of LLF580 in Obese Volunteers." This randomized, double-blind, placebo-controlled study enrolled 61 participants in the United States and evaluated the drug's safety in obese individuals aged 18 years and older.